(Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...
Colossal Biosciences raises $200M in Series C funding led by TWG Global, advancing its innovative de-extinction projects and ...
We are excited to welcome Eric to our Board of Directors,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “His tremendous track record in the pharmaceutical industry as well as his ...
It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...
The de-extinction company led by CEO Ben Lamm has raked in $435 million in funding since its launch. He believes it has ...
Analyst Yanan Zhu from Wells Fargo maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report) and keeping the price target at ...
In BlueAllele Corp. v. Intellia Therapeutics, Inc., 2024 U.S. Dist. Lexis 222094 (D. Del. Dec. 9, 2024)1, the District of ...
Colossal BioSciences has raised $200 million in a new round of funding to bring back extinct species like the woolly mammoth.
Colossal Biosciences, which aims to revive extinct species, announced it has raised an additional $200 million. Critics say ...
The field of precision medicine is rapidly evolving, driven by the integration of big data and multi-omics technologies such as genome sequencing, ...